Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Options Strategies & the Zacks Rank
- AWS 5/20: The Fed In Focus This Week
- PFP 5/20: Will We Touch 1700?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/20/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| NOAH HOLDING | NOAH | 9.92% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Par Pharmaceutical Companies Inc. ( ) recently announced that it has completed the acquisition of India-based generic company Edict Pharmaceuticals. Par Pharma paid $20.5 million at the close of the transaction along with a debt repayment of $4.4 million.
Edict Pharma, located in Chennai, India, develops and manufactures solid oral dosage generic pharmaceuticals and currently has 11 abbreviated new drug applications (ANDA) filed with the US Food and Drug Administration (FDA).
Par Pharma had entered into a definitive agreement to acquire Edict Pharma in May last year. At that time, Par Pharma had said that it expects the transaction to be accretive in 2013.
We note that this acquisition will help boost the company’s revenues. Par Pharma recorded revenues of $215.4 million in the third quarter of fiscal 2011, 8.1% below the year-ago figure of $234.4 million. Lower royalty income and a slip in the sales of the company’s generic products primarily led to the decline.
Par Pharma has been quite active in making acquisitions and entering into deals lately. Last year, in November, the company acquired Anchen Pharmaceuticals for $410 million in cash. Additionally, in October 2011, Par Pharma acquired the rights to three products from Teva Pharmaceutical Industries Ltd. ( TEVA - Analyst Report ) , following the latter’s acquisition of Cephalon.
We currently have a Neutral recommendation on Par Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run. We believe that these acquisitions will help boost the company’s top- and bottom-line, which has been declining in the last few quarters.
Read the full Analyst Report on TEVA